FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 196 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer April 26, 2024 Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... October 30, 2020 Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... May 27, 2025 A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most... May 15, 2020 Load more HOT NEWS Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror Twins Born 15 Minutes Apart Have Birthdays In Different Years Searching for novel connections in cancer metabolism
